Natural substances that may target several facets of AD pathology, such as amyloid aggregation, tau hyperphosphorylation, oxidative stress, and neuroinflammation, are gaining attention due to the drawbacks of conventional drug therapies like acetylcholinesterase inhibitors and amyloid-targeting monoclonal antibodies. The gene discussed is MAPT; the disease is Alzheimer disease.